Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
These are not trivial objections
Both the Kidney Disease Improving Global Outcomes guidelines and American Diabetes Association Standards of Care recommend GLP1-RA as the preferred glucose lowering class for people with T2D and moderate to advanced CKD or ESRD because of their demonstrated cardiovascular benefits in people with T2D at high risk of cardiovascular disease, which includes CKD 13,14
Full data from the trial results announced Thursday will be presented in June at the American Diabetes Association Scientific Sessions, Lilly said, and more results from the overall trial program will be announced and published later this year
Science backed treatment Ongoing clinical support Trusted by 100k customers across the UK Lower starting doses tested: 1mg weekly: Tested in the phase 2 obesity trials as a fixed dose with no escalation
US$ 25.42
US$ 22.60
US$ 20.63
US$ 21.40
US$ 20.52
